Report Details

Home / Reports / Healthcare and Pharmaceutical / Global Metabolic Syndrome Market (2023 Edition): Analysis By Indication (NASH, IRS, Hyper ...

Global Metabolic Syndrome Market (2023 Edition): Analysis By Indication (NASH, IRS, Hypercholesterolemia, Obesity Syndrome, Others), By Molecule Type, Route of Administration, By Region, By Country: Market Insights and Forecast (2018-2028)

Category: Healthcare and Pharmaceutical

Publish Date: June 2023

No. of Pages: 270

Format: Pdf

  • USD

Licensing options

What is Metabolic Syndrome?

Metabolic syndrome, a collection of metabolic ailments that includes obesity, high blood pressure, raised blood sugar levels, and abnormal levels of cholesterol, has emerged as a major global health concern. The condition is frequently associated with major health issues such as cardiovascular disease, type 2 diabetes, and stroke.

Metabolic Syndrome Market Overview

The Metabolic Syndrome Market is expected to witness a robust growth rate in at CAGR 46.30% during the period 2024 to 2028. The market is valued at USD 2222.49 Million in 2021 which is expected to reach USD 28994.63 Million in 2028. The global Metabolic Syndrome market is expected to grow in the coming years, driven by several factors such as the increasing prevalence of Diabetes, growing trend of sedentary lifestyle, rising healthcare expenditure, and the introduction of new and innovative products. 

Metabolic syndrome has attained an epidemic level, with an alarming rise in frequency over the last few years. Factors such as poor diet and the worldwide obesity pandemic have all contributed to the increase in cases. According to the International Diabetes Federation (IDF), metabolic syndrome affects roughly one-quarter of the world's adult population. Obesity and diabetes are becoming more common in both developed and developing countries, increasing the demand for appropriate treatments and management options.

Increasing number of geriatric population

The frequency of metabolic syndrome rises with age, and the elderly population accounts for a sizable proportion of those affected. Obesity, sedentary habits, and chronic illnesses such as diabetes and hypertension become more prevalent as people age.

The worldwide geriatric population is on the rise, owing mostly to greater life expectancy and lower birth rates. According to the World Health Organization, the number of persons aged 60 and more is expected to more than double by 2050. This demographic shift suggests a greater consumer base for products and services connected to metabolic syndrome. The growing elderly population has a direct impact on the industry by increasing demand for efficient management and treatment solutions.

Lack of Awareness 

A lack of knowledge regarding metabolic syndrome may result in underutilization of existing therapies and interventions. Even if effective therapies and medicines are available, people who are uninformed of their ailment are less likely to seek medical attention or adhere to prescribed treatments. Underutilization can stifle market growth by reducing demand for pharmacological interventions and other treatment modalities.

Segment-Wise Insights

Insulin Resistance Syndrome segment accounts for USD 1128.87 Million in 2021

Insulin resistance syndrome is becoming more of a global concern as a result of factors such as sedentary lifestyles, poor dietary habits, and obesity. The rising prevalence of the syndrome directly contributes to market growth by increasing demand for diagnostic tests, therapies, and management techniques.

Pharmaceutical companies are vital to the metabolic syndrome business because they create and market insulin resistance and related medications. 

Among these are medications that improve insulin sensitivity and lower blood glucose levels. The need for such medications has increased as healthcare practitioners focus on managing metabolic syndrome and preventing its symptoms.


Regional Insights        

According to Azoth Analytics Estimates, Asia Pacific accounts for the largest revenue share in 2021. Factors driving the growth of the market include a growing aging population, increasing awareness about Metabolic health, and advancements in product design and technology. Additionally, the rise in obesity and related health issues such as diabetes and hypertension is also expected to contribute to the growth of the market. Americas Metabolic Syndrome Market is the fastest growing market with a positive outlook for the future, driven by factors such as an rising obesity rates, increasing awareness about Metabolic syndrome, and advancements in development of novel therapeutics.

Competitive Landscape

Global Metabolic Syndrome Market is fragmented with top 10 companies accounting for a significant revenue share in the year 2021. Leading companies and brands in the market are executing different strategies and partnerships to strengthen the foothold and increase the competitiveness and product offerings in the market.

Novo Nordisk, Eli Lilly and Company, Takeda Pharmaceuticals, Pfizer and Merk among others are the leading companies in the Global Metabolic Syndrome Market.

Leading companies in the Global Metabolic Syndrome Market include:

  • Novo Nordisk
  • Eli Lilly and Company 
  • Takeda Pharmaceutical 
  • Sanofi
  • AstraZeneca
  • Amgen
  • Merck Co., Inc.
  • Johnson & Johnson
  • Pfizer
  • Abbott

Strategic Developments in the Metabolic Syndrome Market

  • May, 2022: Novo Nordisk collaborated with Flagship Pioneering for cardiometabolic and rare disease
  • Jan, 2023: AstraZeneca acquired CinCor Pharma for its drug baxdrostat (CIN-107) for Hypertension Management

Segmentations in the Report

By Indication 

  • Insulin Resistance Syndrome
  • Hypercholesterolemia
  • Obesity Syndrome
  • Nonalcoholic steatohepatitis
  • Other  Indications

By Molecule Type

  • Small Molecule
  • Protein
  • Other Molecules

By Route of Administration

  • Oral
  • Subcutaneous
  • Other ROA

By Region

  • Americas 
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Frequently Asked Questions

What is the expected market value of Metabolic Syndrome Market in 2028?

Global Metabolic Syndrome Market is expected to be valued at USD 28994.63 Million in 2028. 

At what growth rate is Metabolic Syndrome Market expected to grow in the forecast period?

During  2024-2028, Metabolic Syndrome Market is expected to grow at CAGR of 46.30%.

Which Region Dominates the Metabolic Syndrome Market?

Asia Pacific contributes the largest revenue share in the Metabolic Syndrome Market.

At what rate will America's Metabolic Syndrome Market Grow?

During 2024-2028, Americas Metabolic Syndrome Market is expected to grow at a CAGR of 51.17%

One can also purchase any particular sections from this report. Please send us an email to with your order details.

Need More Help? Contact us Right now!

No matter the hour, we’re here to help.

Contact us now!